Today: 21 May 2026
Fabrinet stock slides after T. Rowe Price filing as tech shares dip
8 January 2026
1 min read

Fabrinet stock slides after T. Rowe Price filing as tech shares dip

New York, Jan 8, 2026, 15:42 EST — Regular session

Fabrinet shares fell 6.5% to $439.75 in afternoon trade on Thursday, down $30.75 from the prior close, after touching a session low of $431.20.

The drop tracked declines across electronics contract manufacturers and AI-linked hardware, with Celestica down 6.3%, Sanmina off 3.7% and Nvidia lower by about 2%.

Separately, T. Rowe Price Associates disclosed in a Schedule 13G filing that it held 4.04 million Fabrinet shares, or 11.3% of the company, as of Dec. 31. Schedule 13G is a short-form report used by investors who cross the 5% ownership threshold without a control intent.

In the broader market, the S&P 500 technology index was down 1.7% as investors turned more selective on stocks tied to artificial-intelligence spending. “It’s become a ‘show me’ sector,” said Art Hogan, chief market strategist at B. Riley Wealth. Reuters

Fabrinet, which makes optical communication components and other precision products for equipment makers, last reported quarterly revenue of $978.1 million and adjusted earnings of $2.92 a share. The company forecast December-quarter revenue of $1.05 billion to $1.10 billion and adjusted earnings of $3.15 to $3.30 per share.

The selloff leaves investors looking for the next signpost on demand for optical gear and related data-center builds, where order timing can swing quickly and move sentiment with it.

Fabrinet has warned that supply constraints, swings in customer demand and reliance on a small group of customers and suppliers could hit results if orders slow or parts are hard to source.

Stock Market Today

  • Australia Shares Set to Rise at Open, New Zealand Markets Dip
    May 20, 2026, 7:49 PM EDT. Australian shares are expected to open higher, signaling investor confidence in the region's market outlook. In contrast, New Zealand equities are projected to decline at the open, reflecting differing economic or market responses. Market data sourced from ICE Data Services with reference information provided by FactSet, supported by multiple financial data providers. The divergence underscores the varied regional market trends in Oceania at the start of the trading session.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking
Previous Story

Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking

Sandisk (SNDK) stock drops after CES-fueled surge cools, with earnings next
Next Story

Sandisk (SNDK) stock drops after CES-fueled surge cools, with earnings next

Go toTop